Tilianin Ameliorates Cognitive Dysfunction and Neuronal Damage in Rats with Vascular Dementia via p-CaMKII/ERK/CREB and ox-CaMKII-Dependent MAPK/NF-κB Pathways.

Abstract

Vascular dementia (VaD) is a common cause of cognitive decline and dementia of vascular origin, but the precise pathological mechanisms are unknown, and so effective clinical treatments have not been established. Tilianin, the principal active compound of total flavonoid extract from Dracocephalum moldavica L., is a candidate therapy for cardio-cerebrovascular diseases in China. However, its potential in the treatment of VaD is unclear. The present study is aimed at investigating the protective effects of tilianin on VaD and exploring the underlying mechanism of the action. A model of VaD was established by permanent 2-vessel occlusion (2VO) in rats. Human neurons (hNCs) differentiated from human-induced pluripotent stem cells were used to establish an oxygen-glucose deprivation (OGD) model. The therapeutic effects and potential mechanisms of tilianin were identified using behavioral tests, histochemistry, and multiple molecular biology techniques such as Western blot analysis and gene silencing. The results demonstrated that tilianin modified spatial cognitive impairment, neurodegeneration, oxidation, and apoptosis in rats with VaD and protected hNCs against OGD by increasing cell viability and decreasing apoptosis rates. A study of the mechanism indicated that tilianin restored p-CaMKII/ERK1/2/CREB signaling in the hippocampus, maintaining hippocampus-independent memory. In addition, tilianin inhibited an ox-CaMKII/p38 MAPK/JNK/NF-κB associated inflammatory response caused by cerebral oxidative stress imbalance in rats with VaD. Furthermore, specific CaMKIIα siRNA action revealed that tilianin-exerted neuroprotection involved increase of neuronal viability, inhibition of apoptosis, and suppression of inflammation, which was dependent on CaMKIIα. In conclusion, the results suggested the neuroprotective effect of tilianin in VaD and the potential mechanism associated with dysfunction in the regulation of p-CaMKII-mediated long-term memory and oxidation and inflammation involved with ox-CaMKII, which may lay the foundation for clinical trials of tilianin for the treatment of VaD in the future.

• Authors: Hailun Jiang, Ghulam Md Ashraf, Mimin Liu, Kaiyue Zhao, Yu Wang, Linlin Wang, Jianguo Xing, Badrah S Alghamdi, Zhuorong Li, Rui Liu
• Journal: Oxidative medicine and cellular longevity (Oxid Med Cell Longev) Vol. 2021 Pg. 6673967 ( 2021) ISSN: 1942-0994 [Electronic] United States
• PMID: 34527176 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Hailun Jiang et al.

Chemical References

• CREB1 protein, human
• Cyclic AMP Response Element-Binding Protein
• Flavonoids
• Glycosides
• NF-kappa B
• Neuroprotective Agents
• RNA, Small Interfering
• tilianin
• Calcium-Calmodulin-Dependent Protein Kinase Type 2
• Extracellular Signal-Regulated MAP Kinases

Topics

• Animals
• Apoptosis (drug effects)
• Calcium-Calmodulin-Dependent Protein Kinase Type 2 (antagonists & inhibitors, genetics, metabolism)
• Cyclic AMP Response Element-Binding Protein (metabolism)
• Dementia, Vascular (drug therapy, metabolism)
• Disease Models, Animal
• Extracellular Signal-Regulated MAP Kinases (metabolism)
• Flavonoids (chemistry, pharmacology, therapeutic use)
• Glycosides (chemistry, pharmacology, therapeutic use)
• Hippocampus (metabolism)
• Humans
• Lamiaceae (chemistry, metabolism)
• Male
• Maze Learning (drug effects)
• NF-kappa B (metabolism)
• Neuroprotective Agents (chemistry, pharmacology, therapeutic use)
• RNA Interference
• RNA, Small Interfering (metabolism)
• Rats
• Rats, Sprague-Dawley
• Signal Transduction (drug effects)